Tempest Therapeutics Inc. Company Profile
NASDAQ: TPSTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Tempest Therapeutics at a glance
Tempest Therapeutics Inc. (NASDAQ: TPST) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Brisbane, CA. Tempest Therapeutics is led by Dr. Matthew Angel Ph.D. and employs about 4 people. At a market capitalization of $5.7 million, it is considered a small-cap company.
Its SEC Central Index Key (CIK) is 0001544227, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Tempest Therapeutics do?
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study; and has a product development and investigator-initiated trial collaboration agreement with Heibei Senlang Biotechnology Co., Ltd. to develop TPST-4003 product candidate. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.
Business description based on the company's public filings.
Company information
- Legal name
- Tempest Therapeutics Inc.
- Ticker
- NASDAQ: TPST
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Matthew Angel Ph.D.
- Employees
- 4
- Headquarters
- 2000 Sierra Point Parkway, Brisbane, CA, United States
- Phone
- 415 798 8589
- Website
- tempesttx.com
- Market cap
- $5.74M
- SEC CIK
- 0001544227
- Latest annual report
- 10-K · Mar 30, 2026
Companies similar to Tempest Therapeutics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| LGVNLongeveron Inc. Class A | 1.66 | -8.79% | $5.60M | vs TPST |
| XCURExicure Inc. | 0.9001 | -12.82% | $5.89M | vs TPST |
| TOVXTheriva Biologics Inc. | 0.12 | -6.25% | $5.51M | vs TPST |
| ENVBEnveric Biosciences Inc. | 1.35 | -4.26% | $6.04M | vs TPST |
| UPCUniverse Pharmaceuticals Inc. Class A | 1.08 | -20.59% | $5.43M | vs TPST |
| ADXNAddex Therapeutics Ltd ADR | 3.47 | +2.06% | $6.08M | vs TPST |
| CNSPCNS Pharmaceuticals Inc. | 3.56 | -12.75% | $5.25M | vs TPST |
| ACXPAcurx Pharmaceuticals Inc. | 1.04 | +0.97% | $6.30M | vs TPST |